Remdesivir cut coronavirus recovery time by 5 days, company’s final study suggests

Final data from Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.

In patients who were on oxygen when they first got the drug, remdesivir – sold under the brand Veklury – reduced recovery time by seven days compared with placebo after 29 days, according to the 1,062-patient study, published in the New England Journal of Medicine.

Read more: Health Canada authorizes remdesivir to treat severe COVID-19

The final study looked at data at 29 days of treatment, versus a preliminary study released in May that reported results after 15 days.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Gilead’s drug was among the first to be used as a treatment for the novel coronavirus, and was one of the drugs recently used to treat U.S. President Donald Trump.

Story continues below advertisement

Click to play video 'Health Matters: Health Canada gives remdesivir the green light' Health Matters: Health Canada gives remdesivir the green light

Health Matters: Health Canada gives remdesivir the green light

Remdesivir received emergency use authorization from the U.S. Food and Drug Administration on May 1, and has since been authorized for use in several other countries.

Results of the overall study suggested the drug may reduce mortality, but the benefit was not statistically significant. In a separate analysis looking just at patients who received oxygen, however, the drug appeared to reduce the risk of death by 72 percent at day 15, and 70 percent by day 29.

Read more: Experts slam U.S. for hoarding world’s supply of remdesivir — only licensed COVID-19 drug

With this analysis, “we now have data suggesting that giving remdesivir to patients on oxygen may significantly reduce their chances of death compared to other subgroups,” Dr. Andre Kalil, an infectious disease expert at the University of Nebraska Medical Center and the study’s principal investigator, said in a press release.

Story continues below advertisement

(Reporting by Julie Steenhuysen Editing by Chris Reese and Sonya Hepinstall)

© 2020 Reuters

Read The Full Article At Global News. This content is provided by Global News at public RSS feed. Please contact us if you have any questions.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.